GeneDx Investors Face August Deadline in Securities Class Action

Investors who lost more than $100,000 in GeneDx Holdings Corp. stock between April 2025 and May 2026 have until August 3 to apply as lead plaintiffs in a pending class action lawsuit. The case, filed in the District of Connecticut, centers on allegations that the company withheld material financial information.

The litigation follows a sharp decline in GeneDx's market performance on May 4, 2026, when the firm reported a drop in adjusted gross margins from 74% to 69%. The company also missed revenue targets for its exome and genome product lines and slashed its full-year revenue guidance from a range of $540–$550 million down to $475–$490 million. Additionally, executives disclosed a $31.2 million impairment loss linked to the acquisition of Fabric Genomics, a deal previously promoted as a transformative expansion of the company’s revenue streams. Following these disclosures, the company's share price plummeted by $33.42, representing a 49.2% loss in value. ClaimsFiler is currently facilitating outreach for affected shareholders to consult with attorneys at Kahn Swick & Foti, LLC regarding the legal proceedings designated as Basma v. GeneDx Holdings Corp., No. 26-cv-00880.